Our Research
Led by Dr. Deanna Kelly, the Treatment Research Program (TRP) at the Maryland Psychiatric Research Center is dedicated to advancing personalized treatment strategies for individuals with schizophrenia. Our team’s research aims to tailor therapies based on the unique biological and clinical characteristics of each patient, focusing particularly on underexplored areas in schizophrenia care.
Women and Schizophrenia
Dr. Kelly’s team is one of the few research groups that specifically investigates the biological differences and treatment side effects experienced by women with schizophrenia. By recognizing and addressing these gender-specific challenges, the team is working to create more effective, personalized treatment options for women with the condition.
Clozapine and Genetic Predispositions
Another major focus of TRP’s research is improving the use of clozapine, a medication for treatment-resistant schizophrenia. The team is leading a large multinational clinical trial aimed at optimizing clozapine treatment, particularly in patients of African descent. This population may have a genetic predisposition to certain side effects, and the study is designed to ensure safe and effective use of clozapine for these individuals, addressing the specific genetic factors that may influence their response to the drug.
Innovations in Technology and Biomarkers
The TRP is also at the forefront of integrating new technologies into schizophrenia research. This includes innovative methods for analyzing language and social media to track symptoms, advanced techniques for detecting medication levels in the body, and the development of novel biomarkers to enhance diagnosis and treatment precision.
Dietary Intervention
Dr. Kelly’s team has extensive experience researching the connection between diet and schizophrenia, particularly in relation to inflammation and immune responses. In collaboration with Johns Hopkins University and Harvard, the group has explored dietary factors like gluten sensitivity, discovering that some individuals with schizophrenia exhibit elevated antibodies against gliadin, a protein found in wheat and other grains. Our research has contributed to a deeper understanding of how dietary changes, such as adopting a gluten-free diet, may benefit certain patients by reducing inflammation and improving psychiatric outcomes.
Building on this expertise, our team has also studied the medical ketogenic diet and its potential to support brain health and symptom management in schizophrenia. In addition, we are currently running a study on prebiotics, actively exploring how these supplements can improve gut health and further enhance mental well-being through better immune regulation.
Referral Process and Participation Opportunities
The TRP is actively enrolling new participants for a variety of research studies, including behavioral studies, medication trials, and more. We welcome individuals with and without a history of mental illness to participate. Our studies offer an opportunity to contribute to the advancement of schizophrenia research while receiving cutting-edge care.